Competing risks and multistate models

Clinical Cancer Research

Volumn 19, Issue 1, 2013, Pages 12-21

  Schmoor, Claudia ^a   Schumacher, Martin ^a   Finke, Jürgen ^a   Beyersmann, Jan ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; THYMOCYTE ANTIBODY;

ARTICLE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MORTALITY; MYELOABLATIVE CONDITIONING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ALGORITHMS; ANTILYMPHOCYTE SERUM; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, STATISTICAL; RECURRENCE;

EID: 84871992475     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1619     Document Type: Article

References (32)

1. Horton N, Switzer S. Statistical methods in the journal. N Engl J Med 2005;353:1977-9.
2. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival endpoint reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008;26:3721-6.
3. Le Tourneau C, Michiels S, Gan H, Siu LL. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. J Clin Oncol 2009;27:5965-71.
4. Klein J, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001;28:909-15.
5. Klein J, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part II: regression modeling. Bone Marrow Transplant 2001;28:1001-11.
6. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008;100:1058-67.
7. Cuzick J. Primary endpoints for randomised trials of cancer therapy. Lancet 2008;371:2156-8.
8. Mell L, Jeong J. Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 2010;28:4297-9.
9. Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. New York: Springer; 2012.
10. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. for the ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in hematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multi-centre phase III trial. Lancet Oncol 2009;10:855-64.
11. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117:6375-82.
12. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res 2012;18:2301-8.
13. Chappell R. Copeting risk analyses: how are they different and why should you care? Clin Cancer Res 2012;18:2127-9.
14. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002;11:91-115.
15. Cox DR. Regression models and life-tables. J Roy Stat Soc B 1972;34:187-220.
16. Aalen O, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 1978;5:141-50.
17. Fine JP, Gray RJ. A proportional hazards model for subdistribution of competing risk. J Am Stat Assoc 1999;94:496-609.
18. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010;45:1388-95.
19. Kim H. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13:559-65.
20. Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. Stat Med 2012;31:1074-88.
21. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
22. Grambauer N, Schumacher M, Beyersmann J. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Stat Med 2010;29:875-84.
23. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-14.
24. van Walraven C, Davis D, Forster A, Wells G. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004;57:672-82.
25. Beyersmann J, Wolkewitz M, Schumacher M. The impact of time-dependent bias in proportional hazards modeling. Stat Med 2008;27:6439-54.
26. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
27. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009;101:581-91.
28. Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst 2010:102:1468-77.
29. Andersen PK, Abildstrom SZ, Rosthoj S. Competing risks as a multistate model. Stat Methods Med Res 2002;11:203-15.
30. Latouche A, Porcher R. Sample size calculations in the presence of competing risks. Stat Med 2007;26:5370-80.
31. Schulgen G, Olschewski M, Krane V, Wanner C, Ruf G, Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 2005;26:386-95.
32. Allignol A, Schumacher M, Wanner C, Drechsler C, Beyersmann J. Understanding competing risks: a simulation point of view. BMC Med Res Methodol 2011;11:86.